AusperBio is a biotechnology company focused on developing oligonucleotide therapeutics and targeted delivery technologies.
AusperBio has raised $120.0M in total funding. The most recent round was Series C. The last funding was announced in August 2026.
AusperBio's investors include RA Capital Management, Qiming Venture Partners, CDH Investments, Genesis Capital, BioVenture.
AusperBio is headquartered in San Mateo, United States.
AusperBio is a biotechnology company focused on developing oligonucleotide therapeutics and targeted delivery technologies.
AusperBio is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AusperBio — Funding & Investors." VCBacked, August 27, 2026, https://www.vcbacked.co/company/ausperbio. Accessed September 3, 2026.
VCBacked. (2026). AusperBio — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/ausperbio
{{cite web |title=AusperBio — Funding & Investors |url=https://www.vcbacked.co/company/ausperbio |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated